Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program.

被引：5

作者：

Itzykson, Raphael ^{[1
]}

Thepot, Sylvain ^{[1
]}

Recher, Christian ^{[2
]}

Delaunay, Jacques ^{[3
]}

Quesnel, Bruno ^{[4
]}

Dreyfus, Francois ^{[5
]}

Koka, Anne Marfaing ^{[6
]}

Vey, Norbert ^{[7
]}

Stamatoullas, Aspasia ^{[8
]}

Gyan, Emmanuel ^{[9
]}

Cluzeau, Thomas ^{[10
]}

Rousselot, Philippe ^{[11
]}

Reman, Oumedaly ^{[12
]}

Plantier, Isabelle ^{[13
]}

Marolleau, Jean Pierre ^{[14
]}

More, Pierre ^{[15
]}

Wattel, Eric ^{[16
]}

Visanica, Sorin ^{[17
]}

Zerhouni, Chahinez ^{[1
]}

Bordessoule, Dominique ^{[18
]}

Ades, Lionel

Fenaux, Pierre ^{[19
,20
]}

Gardin, Claude

机构：

[1] GFM, Bobigny, France

[2] CHU Purpan, Toulouse, France

[3] CHU Nantes, F-44035 Nantes 01, France

[4] CHRU, Lille, France

[5] Hop Cochin, AP HP, F-75674 Paris, France

[6] Hop Antoine Beclere, AP HP, Clamart, France

[7] Inst J Paoli I Calmettes, F-13009 Marseille, France

[8] Ctr Henri Becquerel, F-76038 Rouen, France

[9] CHU Tours, Tours, France

[10] CHU, Nice, France

[11] CH, Versailles, France

[12] CHU Caen, F-14000 Caen, France

[13] CH, Roubaix, France

[14] CHU, Amiens, France

[15] CH, Lens, France

[16] Hop Edouard Herriot, Lyon, France

[17] CHR, Metz, France

[18] CHU, Limoges, France

[19] Univ Paris 13, Hop Avicenne, AP HP, Bobigny, France

[20] Inst Gustave Roussy, INSERM 848, Bobigny, France

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

10.1182/blood.V114.22.843.843

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：436 / 436

页数：1

共 50 条

[21] Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program
Damaj, G.
Malard, F.
Hulin, C.
Caillot, D.
Garidi, R.
Royer, B.
Marit, G.
Stoppa, A. M.
Banos, A.
Morineau, N.
Moreau, P.
Fitoussi, O.
Tiab, M.
Moreau, P.
LEUKEMIA & LYMPHOMA, 2012, 53 (04) : 632 - 634
[22] Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia:: results of a prospective trial
Martino, R
Bellido, M
Brunet, S
Altés, A
Sureda, A
Guárdia, R
Aventín, A
Nomedéu, JF
Domingo-Albós, A
Sierra, J
HAEMATOLOGICA, 1999, 84 (06) : 505 - 510
[23] Safety and Dosimetric Analysis of Lintuzumab-Ac225 in Combination with Intensive CLAG-M Chemotherapy in Patients with Relapsed/Refractory AML
Abedin, Sameem
Brodin, Patrik
Chen, Mary
Rotibi, Mojisola
Syed, Umar
Desai, Avinash
Atallah, Ehab
JOURNAL OF NUCLEAR MEDICINE, 2024, 65
[24] A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
Park, Silvia
Kwag, Daehun
Kim, Tong Yoon
Lee, Jong Hyuk
Lee, Joon Yeop
Min, Gi June
Park, Sung Soo
Yahng, Seung-Ah
Jeon, Young-Woo
Shin, Seung-Hwan
Yoon, Jae-Ho
Lee, Sung-Eun
Cho, Byung Sik
Eom, Ki-Seong
Kim, Yoo-Jin
Lee, Seok
Min, Chang-Ki
Cho, Seok-Goo
Lee, Jong Wook
Kim, Hee-Je
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
[25] LARGE SCALE, REAL-WORLD RESULTS ON IBRUTINIB FOR 428 FRENCH PATIENTS WITH 17P DELETION OR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM
Ysebaert, L.
Aurran-Schleinitz, T.
Dartigeas, C.
Dilhuydy, M. S.
Feugier, P.
Michallet, A. S.
Tournilhac, O.
Dupuis, J.
Sinet, P.
Albrecht, C.
Cymbalista, F.
HAEMATOLOGICA, 2016, 101 : 57 - 58
[26] Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
Dumas, Pierre-Yves
Raffoux, Emmanuel
Berard, Emilie
Bertoli, Sarah
Hospital, Marie-Anne
Heiblig, Mael
Desbrosses, Yohann
Bonmati, Caroline
Pautas, Cecile
Lambert, Juliette
Orvain, Corentin
Banos, Anne
Pasquier, Florence
Peterlin, Pierre
Marchand, Tony
Uzunov, Madalina
Frayfer, Jamile
Turlure, Pascal
Cluzeau, Thomas
Jourdan, Eric
Himberlin, Chantal
Tavernier, Emmanuelle
Villate, Alban
Haiat, Stephanie
Chretien, Marie-Lorraine
Carre, Martin
Chantepie, Sylvain
Vaida, Ioana
Wemeau, Mathieu
Chebrek, Safia
Guillerm, Gaelle
Guieze, Romain
Debarri, Houria
Gehlkopf, Eve
Laribi, Kamel
Marcais, Ambroise
Santagostino, Alberto
Bene, Marie-Christine
Mineur, Ariane
Pigneux, Arnaud
Dombret, Herve
Recher, Christian
LEUKEMIA, 2023, 37 (01) : 91 - 101
[27] Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
Dumas, Pierre-Yves
Raffoux, Emmanuel
Berard, Emilie
Bertoli, Sarah
Hospital, Marie Anne
Heiblig, Mael
Desbrosses, Yohan
Bonmati, Caroline
Pautas, Cecile
Lambert, Juliette
Orvain, Corentin
Banos, Anne
Pasquier, Florence
Peterlin, Pierre
Marchand, Tony
Uzunov, Madalina
Frayfer, Jamile
Turlure, Pascal
Cluzeau, Thomas
Jourdan, Eric
Himberlin, Chantal
Tavernier, Emmanuelle
Villate, Alban
Haiat, Stephanie
Chretien, Marie-Lorraine
Carre, Martin
Chantepie, Sylvain
Vaida, Iona
Wemeau, Mathieu
Chebrek, Safia
Guillerm, Gaelle
Guieze, Romain
Debarri, Houria
Gehlkopf, Eve
Laribi, Kamel
Marcais, Ambroise
Santagostino, Alberto
Bene, Marie C.
Mineur, Ariane C.
Pigneux, Arnaud
Dombret, Herve
Recher, Christian
BLOOD, 2022, 140 : 8996 - 8998
[28] Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
Pierre-Yves Dumas
Emmanuel Raffoux
Emilie Bérard
Sarah Bertoli
Marie-Anne Hospital
Maël Heiblig
Yohann Desbrosses
Caroline Bonmati
Cécile Pautas
Juliette Lambert
Corentin Orvain
Anne Banos
Florence Pasquier
Pierre Peterlin
Tony Marchand
Madalina Uzunov
Jamilé Frayfer
Pascal Turlure
Thomas Cluzeau
Eric Jourdan
Chantal Himberlin
Emmanuelle Tavernier
Alban Villate
Stephanie Haiat
Marie-Lorraine Chretien
Martin Carre
Sylvain Chantepie
Ioana Vaida
Mathieu Wemeau
Safia Chebrek
Gaelle Guillerm
Romain Guièze
Houria Debarri
Eve Gehlkopf
Kamel Laribi
Ambroise Marcais
Alberto Santagostino
Marie-Christine Béné
Ariane Mineur
Arnaud Pigneux
Hervé Dombret
Christian Récher
Leukemia, 2023, 37 : 91 - 101
[29] Ivosidenib (IVO) Prior to Hematopoietic Cell Transplant (HCT) for Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Who Cannot Tolerate Intensive Chemotherapy (IC)
DiNardo, Courtney D.
Stein, Eytan M.
Pigneux, Arnaud
Altman, Jessica K.
Collins, Robert
Erba, Harry P.
Watts, Justin M.
Uy, Geoffrey L.
Wu, Bin
Choe, Sung
Kapsalis, Stephanie M.
Liu, Hua
Winkler, Thomas
Roboz, Gail J.
de Botton, Stephane
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S197 - S198
[30] 5-Azacytidine (AZA) Compared to Intensive Chemotherapy in Elderly Acute Myeloid Leukemia (AML) Patients: Results of a Retrospective Single Centre Matched Analysis
Lestang, Elsa
Ayari, Sameh
Chevallier, Patrice
Guillaume, Thierry
Rialland, Fanny
Blin, Nicolas
Fayad, Nadia
Clavert, Aline
Roland, Virginie
Gastinne, Thomas
Mahe, Beatrice
Dubruille, Viviane
Le Gouill, Steven
Moreau, Philippe
Mohty, Mohamad
Delaunay, Jacques
BLOOD, 2011, 118 (21) : 1546 - 1547

← 1 2 3 4 5 →